BNTX – BioNTech SE
BioNTech SEBNTX
$102.67Name : BioNTech SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $24,687,560,704.00
EPSttm : -2.78
BioNTech SE
$102.67
0.41%$0.42Float Short %
2.55
Margin Of Safety %
Put/Call OI Ratio
0.78
EPS Next Q Diff
-1.89
EPS Last/This Y
-0.79
EPS This/Next Y
0.53
Price
102.74
Target Price
140.65
Analyst Recom
1.61
Performance Q
-7.84
Relative Volume
0.87
Beta
1.29
Ticker: BNTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | BNTX | 107.95 | 0.95 | 0.69 | 39622 |
| 2025-10-21 | BNTX | 106.99 | 0.95 | 0.45 | 39929 |
| 2025-10-22 | BNTX | 105.87 | 0.94 | 0.12 | 40399 |
| 2025-10-23 | BNTX | 104.75 | 0.93 | 1.22 | 40639 |
| 2025-10-24 | BNTX | 105.65 | 0.94 | 0.32 | 40881 |
| 2025-10-27 | BNTX | 106.09 | 0.94 | 0.42 | 40976 |
| 2025-10-28 | BNTX | 105.05 | 0.94 | 0.30 | 41016 |
| 2025-10-29 | BNTX | 103.29 | 0.93 | 0.43 | 41081 |
| 2025-10-30 | BNTX | 104.66 | 0.94 | 0.19 | 41113 |
| 2025-10-31 | BNTX | 103.98 | 0.92 | 0.78 | 41797 |
| 2025-11-03 | BNTX | 103.94 | 0.92 | 0.60 | 41930 |
| 2025-11-04 | BNTX | 104.95 | 0.92 | 0.05 | 42089 |
| 2025-11-05 | BNTX | 103.5 | 0.84 | 0.92 | 44078 |
| 2025-11-06 | BNTX | 103.43 | 0.84 | 1.26 | 44010 |
| 2025-11-07 | BNTX | 103.15 | 0.84 | 0.46 | 44110 |
| 2025-11-10 | BNTX | 105.04 | 0.84 | 0.28 | 44201 |
| 2025-11-11 | BNTX | 108.72 | 0.83 | 0.20 | 44466 |
| 2025-11-12 | BNTX | 111.61 | 0.77 | 1.13 | 47228 |
| 2025-11-13 | BNTX | 103.88 | 0.78 | 0.53 | 48161 |
| 2025-11-14 | BNTX | 103.03 | 0.77 | 1.40 | 49250 |
| 2025-11-17 | BNTX | 102.75 | 0.78 | 3.11 | 49564 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | BNTX | 107.95 | -96.2 | -1013.8 | -4.02 |
| 2025-10-21 | BNTX | 107.00 | -86.5 | -873.7 | -4.01 |
| 2025-10-22 | BNTX | 106.23 | -86.5 | -879.0 | -4.01 |
| 2025-10-23 | BNTX | 104.67 | -85.3 | -854.8 | -4.02 |
| 2025-10-24 | BNTX | 105.64 | -87.7 | -948.7 | -4.05 |
| 2025-10-27 | BNTX | 106.02 | -87.7 | -930.8 | -4.05 |
| 2025-10-28 | BNTX | 105.03 | -87.7 | -883.9 | -4.05 |
| 2025-10-29 | BNTX | 103.36 | -87.7 | -861.2 | -4.05 |
| 2025-10-30 | BNTX | 104.67 | -87.7 | -973.7 | -4.05 |
| 2025-10-31 | BNTX | 103.91 | -87.7 | -898.2 | -4.05 |
| 2025-11-03 | BNTX | 103.96 | -87.7 | -915.0 | -4.05 |
| 2025-11-04 | BNTX | 104.83 | -87.7 | -928.3 | -4.05 |
| 2025-11-05 | BNTX | 103.37 | -87.7 | -845.3 | -4.05 |
| 2025-11-06 | BNTX | 103.33 | -172.5 | -890.0 | -4.19 |
| 2025-11-07 | BNTX | 103.14 | -84.8 | -884.8 | -3.24 |
| 2025-11-10 | BNTX | 105.07 | -84.8 | -787.1 | -3.24 |
| 2025-11-11 | BNTX | 108.65 | -107.0 | -837.6 | -4.23 |
| 2025-11-12 | BNTX | 111.64 | -107.0 | -810.7 | -4.23 |
| 2025-11-13 | BNTX | 103.82 | -113.5 | -536.4 | -4.13 |
| 2025-11-14 | BNTX | 103.06 | -113.5 | -710.4 | -4.13 |
| 2025-11-17 | BNTX | 102.74 | -113.5 | -909.4 | -4.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | BNTX | 0.00 | 1.45 | 2.63 |
| 2025-10-21 | BNTX | 0.00 | 1.45 | 2.63 |
| 2025-10-22 | BNTX | 0.00 | 1.45 | 2.63 |
| 2025-10-23 | BNTX | 0.00 | 1.45 | 2.63 |
| 2025-10-24 | BNTX | 0.00 | 1.45 | 2.63 |
| 2025-10-27 | BNTX | 0.00 | 1.51 | 2.61 |
| 2025-10-28 | BNTX | 0.00 | 1.51 | 2.61 |
| 2025-10-29 | BNTX | 0.00 | 1.51 | 2.61 |
| 2025-10-30 | BNTX | 0.00 | 1.51 | 2.61 |
| 2025-10-31 | BNTX | 0.00 | 1.51 | 2.61 |
| 2025-11-03 | BNTX | 0.00 | 1.47 | 2.61 |
| 2025-11-04 | BNTX | 0.00 | 1.47 | 2.61 |
| 2025-11-05 | BNTX | 0.00 | 1.47 | 2.61 |
| 2025-11-06 | BNTX | 0.00 | 1.47 | 2.61 |
| 2025-11-07 | BNTX | 0.00 | 1.47 | 2.61 |
| 2025-11-10 | BNTX | 0.00 | 0.77 | 2.61 |
| 2025-11-11 | BNTX | 0.00 | 0.77 | 2.61 |
| 2025-11-12 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-13 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-14 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-17 | BNTX | 0.00 | 1.58 | 2.55 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
-2.03
Insider Transactions
Institutional Transactions
1.58
Beta
1.29
Average Sales Estimate Current Quarter
813
Average Sales Estimate Next Quarter
219
Fair Value
Quality Score
56
Growth Score
33
Sentiment Score
8
Actual DrawDown %
77.9
Max Drawdown 5-Year %
-82.2
Target Price
140.65
P/E
Forward P/E
PEG
P/S
6.99
P/B
1.14
P/Free Cash Flow
EPS
-2.63
Average EPS Est. Cur. Y
-4.02
EPS Next Y. (Est.)
-3.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-17.92
Relative Volume
0.87
Return on Equity vs Sector %
-30
Return on Equity vs Industry %
-15.1
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.01
EBIT Estimation
-909.4
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading